Axel Sven Malkomes

Axel Sven Malkomes has more than 3 decades of senior corporate and investment banking experience within the biotechnology and pharmaceutical industries. Axel joined CureVac from Cardior Pharmaceuticals, a private clinical-stage company developing noncoding RNA-based therapeutics for heart disease, where he served as Chief Financial Officer (CFO). He played a crucial role in strategically and financially preparing the company for capital markets, also culminating in the successful acquisition of Cardior by Novo Nordisk in 2024.

Before Cardior, Axel was CFO and Chief Business Officer at publicly listed Medigene AG. His extensive experience also includes senior health care investment banking roles at Barclays, Lehman Brothers, Société Générale, as well as coheading European health care investments at 3i Group plc. Earlier in his career, he held senior leadership positions at Merck KGaA.

Axel holds a degree in business administration from Otto-Friedrich University in Bamberg, Germany, and has completed executive management programs at INSEAD, Kellogg School of Management at Northwestern University, and the Hong Kong University of Science and Technology.